1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
66DE9FE0828F00425002585DC003E1EDF
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-functionality-technology-platforms-during-global-covid-19-pandemic?opendocument
18
19opendocument
203.239.58.199
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




» Products & Services » » Business Operations » Information Technology

Evolution of Technology Platforms during the Global COVID-19 Pandemic and Beyond

ID: 5634


Features:

9 Info Graphics

20 Data Graphics

490+ Metrics

25 Narratives


Pages/Slides: 40


Published: 2020


Delivery Format: Online PDF Document


 

License Options:


Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • STUDY SNAPSHOT
  • KEY FINDINGS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from “Evolution of Technology Platforms during the Global COVID-19 Pandemic and Beyond”

With the COVID-19 pandemic impacting key business operations across the world, organizations have had to adapt or start up new technologies and communication platforms to continue their support of patients and to interact with physicians, thought leaders and other internal and external stakeholders.

As part of our "Managing through COVID-19 and Beyond" benchmark research series, Best Practices LLC conducted this study to track the rapid evolution in virtual infrastructure and digital engagement platforms within life sciences companies as a result of the global COVID-19 pandemic.

This new study examines critical new system functionalities by assessing a wide range of digital communication and collaboration platforms, the frequency usage and effectiveness of various modes of technology, and evolving strategies and approaches for enhancing engagement through innovative operating models in the post-COVID-19 world.

Industries Profiled:
Health Care; Pharmaceutical; Diagnostic; Biotech; Medical Device; Laboratories; Biopharmaceutical; Manufacturing; Consumer Products; Consulting; Science; Marketing; Clinical Research


Companies Profiled:
Abbott; ADC Therapeutics; Advanced Accelerator Applications; Align Technology; Alkem; Alkermes; Allergan; Almirall; Alnylam Pharmaceuticals; AstraZeneca; Bayer; Boehringer Ingelheim; B. Braun; Chiesi; Daiichi Sankyo; Deciphera Pharmaceuticals; DiaSorin; Eisai; EMD Serono; GE Healthcare; Grünenthal; Ipsen; IDEXX Laboratories; Kyowa Kirin; Lundbeck; Merck; Nabriva Therapeutics; Novartis; Proteus Digital Health; Sandoz; Sanofi Genzyme; Santen; Takeda Pharmaceuticals; The Stem; Thermo Fisher Scientific; UCB Pharma; Vifor Pharma; Wellspect HealthCare; West 53rd St Digital; Worldwide Clinical Trials

Study Snapshot

Best Practices, LLC engaged 54 leaders at 40 life sciences organizations in this research. Nearly 70% of the participants are at the director/ head level.

Key topics covered in this research include:

  • Technology implementation achievements and challenges
  • Usage of digital communicative and collaborative platforms
  • Technology used to support internal and external stakeholder communication
  • Internal and external communication approach post-COVID-19
  • Technology change duration


Key Findings

Select key insights uncovered from this research are noted below. Detailed findings are available in the full study.

  • Multifunctional support of technology platforms: Respondents regularly favor digital platforms that provide file sharing, collaboration and communication tools on a single platform. Almost 60% of Microsoft Teams users have increased their use of the platform since the pandemic, while 50% plan to make continue with how they already used Skype for Business. Zoom was the second most adopted platform behind MS Teams.
  • Physician-focused online engagement still lags: Mandatory virtual outreach has necessitated streamlined discussion methods. Unfortunately, e-detailing and e-sampling lack effectiveness at this point.


If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.